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Abstract 
 
Obesity is a major risk factor for diabetes mellitus (DM), 
which is a major global metabolic health disorder currently 
affecting over 460 million people and this number is rising 
rapidly. Heart failure (HF) is the major cause of death among 
diabetic patients. The disorder is due to elevated blood 
glucose or hyperglycemia (HG) beyond physiological level, 
which in turn leads to a number of long-term or end-organ 
complications over time and over 80% of all diabetics will 
eventually die from either HF or cardiomyopathy if left 
untreated. Treatment of DM is very costly and as such, 
patients turn to non-pharmacological or alternative forms of 
treatment, including weight loss, diet modifications and 
plant-based medicines, which are more cost-effective. There 
are several medicinal plants, which are currently used to treat 
for DM and they are known to exhibit anti-diabetic 
properties. One such plant is Momordica charantia, or bitter 
melon, which is used in many tropical countries as a 
traditional functional food and medicine, especially for the 
treatment of obesity, DM, hypertension and cancer. This 
review is related to the anti-oxidant beneficial effect of 
Momordica charantia in the treatment of diabetic 
cardiomyopathy (DCM). The beneficial effects of 
Momordica charantia in the treatment of obesity, diabetes 
and cardiovascular diseases (CVDs) have been reported in 
clinical and experimental animal studies and this review 
addresses some of these useful effects. However, the cellular 
and molecular mechanisms underlying its therapeutic 
antidiabetic effects of M charantia via its anti-oxidant 
activities are not fully known and further research studies 
need to be done. 
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Diabetes mellitus (DM) has been recognized as a 
major cause of morbidity and mortality for decades [1]. 
Hyperglycemia (HG) plays a significant role in the 
development of diabetic cardiomyopathy (DCM). The 
exact mechanisms underlying the disease remain 
incompletely clear. The burden of chronic diseases, 
including cardiovascular diseases (CVDs), renal 
disease, obesity, diabetes and cancers are rapidly 
increasing worldwide. These non-communicable 
diseases (NCDs) have become a major health concern 
to mankind, not just in developed countries but also in 
developing countries [2]. The increasing global 
prevalence of obesity and diabetes poses a huge 
challenge to health services and it reduces the quality 
of life of the patients primarily due to CVDs, which are 
inextricably linked to microvascular complications. As 
declared by the World Health Organization (WHO), 
along with the International Diabetes Federation IDF), 
obesity and DM are currently the modern life-style-
induced diseases of the 21st century. According to the 
IDF, the prevalence of diabetes worldwide had already 
reached 420 million in 2016 and the estimates for 2030 
could reach 630 million people [1]. Six of the top 10 
countries with the highest prevalence of diabetes (in 
adults aged 20 to 79 years) are in the Middle East and 
they are the United Arab Emirates (UAE), Kuwait, 
Lebanon, Qatar, Saudi Arabia and Bahrain [3]. The 
UAE is 16th in the global ranking for countries with 
highest prevalence of diabetes [4]. In 2000, one study 
conducted at Al Ain City estimated that 25 percent of 
UAE nationals were diagnosed with the disorder as 
compared to 19 percent of the non-nationals [5]. This 
chronic disease and its complications pose a significant 
financial burden on the global healthcare systems. The 
average, in terms of medical expenses, in comparison 
to a person without diabetes, is more than twice as high 
for a person with diabetes. The average annual cost of 
diabetes care in UAE was estimated to be $3,995 
(USAD) per patient, rising to as high as $6,175 in 
patients who have developed complications. Globally, 
it costs the Governments of the world about one trillion 
USAD$ to diagnose, treat and care for diabetic patients 
in order to provide them with a better quality of life [4]. 
 
 
Complementary and Alternative Medicines 
 
Herbs and other dietary supplements are used as 
complementary and alternative medicine either to 
avoid or to reduce the use of Western orthodox medical 
treatment. A recent study showed that up to 30% of 
diabetic patients use complementary and alternative 
medicines [6]. Since the ancient times, many plants and 
their extract were used as a treatment for numerous 
diseases, including diabetes. The WHO has listed 21, 
000 plants which are used for medicinal purposes 
around the world. Among them, 150 species are used 
commercially on a fairly large scale [7]. Bitter melon, 
which is also known as Momordica charantia (M. 
charantia), is a well-known plant used for treating and 
preventing diabetes amongst the populations of many 
tropical countries from Asia, South America, India, the 
Caribbean and East Africa [6]. M. charantia, is also 
rich in minerals, including potassium, calcium, zinc, 
magnesium, phosphorus and iron, and is a good source 
of dietary fiber and vitamins [8]. The medicinal value 
of bitter melon has been attributed to its high 
antioxidant properties due in part to phenols, 
flavonoids, isoflavones, terpenes, momordicine, 
anthroquinones and glucosinolates, all of which confer 
a bitter taste [9]. Figure 1 illustrates the bitter melon 
plant and its green fruits. 
 
 
Figure 1. A photograph showing the bitter melon plant and 
its green fruits. 
It has been found that M. charantia has a 
significant antidiabetic as well as hypo-lipidemic 
activity so that it can be used as an adjuvant along with 
allopathic treatment of medicine to treat diabetes as 
well as to delay the late complications associated with 
diabetes, including CVDs [6]. Biochemical and animal 
model experiments have produced abundant data and 
hypotheses accounting for the anti-diabetic effects of 
M. charantia. This review summarizes the active 
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components and medicinal properties of M. charantia, 
especially the activities and mechanisms of its anti-
diabetic effect with particular reference to heart failure 
(HF). Moreover, this review will provide an overview 
regarding the use M. charantia and its medicinal 
potency responsible for the hypoglycemic and hypo-
lipidemic activities in animal and human subjects. 
 
 
M. charantia to Treat Diabetic Mellitus-
Induced Complications 
 
Insulin has a vital role in the regulation of various 
aspects of cardiovascular metabolism and function. In 
fact, the human heart produces and uses between 3.5 
and 5 kg of adenosine triphosphate (ATP) daily to 
pump blood around the body. The energy generation 
depends on the cardiac environment, including 
coronary flow, blood substrate supply, hormones and 
nutritional status [10-12]. DM is characterized by 
reduced glucose and lactate metabolism and increased 
fatty acid (FA) metabolism [13]. In the diabetic heart, 
the myocardial glucose transport is impaired because 
of decreased myocardial concentration of glucose 
transporter type 1 (GLUT1) and type 4 (GLUT4) 
protein and mRNA level [14]. A second mechanism of 
reduced glucose oxidation is via the inhibitory effect of 
FA oxidation on pyruvate dehydrogenase complex due 
to high circulating free fatty acids (FA) [15]. Insulin 
induces glucose uptake in cardiomyocytes by binding 
to insulin receptor (IR). IR undergoes auto-trans-
phosphorylation, which initiates a signaling cascade 
initiated by tyrosine phosphorylation of insulin 
receptor substrates (IRS), followed by phosphorylation 
of phosphatidyl-inositol-3 kinase (PI3K), 
phosphoinositide-dependent kinase 1 (PDK1), Akt, 
and protein kinase C (PKC). These events lead the 
glucose transporter type 1 (GLUT1) and type 4 
(GLUT4) translocation to the membrane to facilitate 
glucose uptake into the cell. In the heart, contractile 
mediated-translocation of GLUT4 represents the major 
mechanism that regulates glucose entry in the beating 
heart, with GLUT1 playing a lesser role [16]. Insulin 
resistance (IR) and hyperinsulinemia are recognized as 
risk factors for DCM [17]. In hyperinsulinemia and 
insulin resistance, a disturbance of insulin-mediated 
glucose metabolism occurs and it can significantly 
worsen metabolic efficiency of both skeletal and 
cardiac muscles. Insulin affects the diabetic heart by 
both systemic metabolism abnormalities and direct 
effects on insulin signaling pathways that are intrinsic 
to the cardiac tissue [18]. In the evolution of insulin 
resistance, the initial change that develops in the hearts 
of animal models is the impairment in the ability of 
insulin to increase glucose transport [19]. A recent 
study revealed that IR is associated with cardiac 
contractile dysfunction. The authors of the study 
generated a new insulin resistant animal rat model on 
high cholesterol fructose (HCF) diet. HCF diet induced 
IR on both metabolic response tissue and the heart as 
well. These findings illustrate that IR is associated with 
metabolic alteration and consequently leading to the 
development of DCM [19]. Circulating FA and 
triglyceride (TG) are increased by enhanced lipolysis 
in adipose tissue and lipoprotein synthesis in liver, 
resulting in hyperglycemia and insulin resistance. 
When the FAs exceed the oxidative capacity of the 
heart, the FAs are converted to lipid like TG or 
ceramide, which can lead to lipo-toxicity and cell 
apoptosis [19]. Thus, DM leads to increased rates of 
FA oxidation and decreased rates of glucose oxidation. 
Specific knowledge about M. charantia may provide 
insight for strategic consumption and sustainable use 
of the plant. The alternate medicine system is now 
gaining strong momentum with the knowledge of 
active principles identified from plant species. M. 
charantia possesses significant anti-obese, antidiabetic 
and hypolipidemic activities so that it can be used as an 
adjuvant, along with allopathic medicine to treat 
diabetes and other related-disorders as well as delaying 
the late complications of diabetes. Thus, the use of M. 
charantia, as treatment, is not a first choice in diabetic 
cardiomyopathy but only an alternative [19, 20]. 
 
 
Chemical Composition of M. charantia  
and Antidiabetic Effects 
 
M. Charantia is a flowering vine in the family 
cucurbitaceous [20]. The green fruit of M. charantia is 
rich in fibres, proteins, vitamin C, carotenoid, phenolic 
content, and anti-oxidant activity, including the 
presence of caffeic and celuic acids and a number of 
cations, including sodium, potassium, calcium, 
magnesium, manganese, copper and zinc. Among the 
cations, the fruit had significantly more sodium and 
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calcium compared to the other cations present [20]. M. 
charantia is composed of plant-based proteins, which 
have a hypoglycemic activity similar to insulin [21]. In 
diabetes, glucose uptake is impaired and the chemical 
impact of M. charantia leads to the activation of a 
protein called AMPK, which regulates fuel metabolism 
and enables glucose uptake. It was found that when M. 
charantia is taken continuously over a long period, it 
increases the ability to substitute the insulin in the body 
[22, 23]. According to a study done on streptozotocin-
STZ-induced type 1 diabetes (T1DM), oral 
administration of the M. charantia extract significantly 
lowered the blood glucose level. Also, blood glucose 
was controlled by stimulating insulin secretion from β 
cells in pancreatic islets isolated from obese-
hyperglycemic mice [7]. Another study demonstrated 
that an aqueous extract  
M. charantia fruit also has hypoglycemic activity in 
cyproheptadine-induced diabetic mice [24]. Orally 
administered M. charantia aqueous extracts lowered 
glucose concentrations independently of intestinal 
glucose absorption and involved extra-pancreatic 
effects [25, 26]. In clinical trials, polypeptide-P 
isolated from the bitter melon was jreported to have 
hypoglycemic activity [27]. With the chronic 
administration of the M. charantia fruit juice at 20 
mg/kg orally, blood glucose tolerance of alloxan-
induced rats was ameliorated significantly from day 7 
to day 22, and was reduced to normal levels [28]. It was 
stated that the mechanism of action by which M. 
charantia extracts control blood glucose level is via 
both intra- and extra-pancreatic mechanisms involving 
beta cells [29]. Additionally, it was found that M. 
charantia can affect the liver by reducing 
glycogenesis, enhancing peripheral glucose utilization 
and increasing serum protein levels [30]. 
 
 
Hyperglycemia, Oxidative Stress  
and Diabetes Mellitus 
 
HG results in tissue damage by both acute 
reversible changes in cellular metabolism and 
irreversible changes in macro-molecules [31]. HG can 
cause long-term damage to multiple organs, resulting 
in severe complication [32, 33]. The microvascular 
system is a key target of HG-induced damage to small 
blood vessels which in turn can initiate systematic 
complication [34, 35]. One major contributor to HG-
induced diabetic abnormalities is increased oxidative 
stress (OS) [36]. The possible biochemical mechanism 
involves increased OS [37] which is characterized by 
the imbalance between free radicals and antioxidants. 
This imbalance could be a result of an increased free 
radical production and/or decreased antioxidants 
capacity [38]. The imbalance between free radicals and 
antioxidant systems gives rise to free radical-mediated 
damage mainly via ROS [39]. ROS can also cause 
damage to the mitochondria together with poly (ADP-
ribose) polymerase-1 (PARP) activation, leading to the 
inhibition of the cytosolic enzyme glyceraldehyde-
3phosphate dehydrogenase (GAPDH). This inhibition 
initiates a series of cellular processes by activation 
pathways leading to HG-induced cellular damage [40]. 
Inhibition of GAPDH diverts glucose from glycolytic 
pathways to alternative biochemical pathways, 
including polyol pathway and AGE formation [41]. 
Under normal physiological conditions, cellular 
glucose is predominantly phosphorylated into glucose 
6-phosphate by hexokinase and it enters the glycolytic 
pathway. Only trace amounts of non-phosphorylated 
glucose (about 3%) enter the polyol pathway [42]. 
However, during HG, there is increased flux through 
the polyol pathway, accounting for greater than 30% of 
glucose metabolism [43]. The polyol pathway converts 
hexose sugars, such as glucose, into sugar alcohols 
(polyols). For example, glucose can be converted into 
sorbitol via the action of the enzyme aldose reductase. 
Aldose reductase is the rate-limiting enzyme for this 
pathway [44]. Increased aldose reductase activity and 
accumulation of sorbitol have been found in diabetic 
animal models. As sorbitol does not easily dissolve 
across cell membranes, this increases cellular 
osmolarity, ultimately leading to cell shrinkage and 
subsequently, damage. Sorbitol may also glycate 
nitrogen molecules on proteins, such as collagen, 
producing AGE-related products [44]. Increased 
polyol flux is associated with reduced levels of 
intracellular glutathione and an increase in cardiac cell 
apoptosis [45]. 
M. charantia has a beneficial effect on most 
metabolic and physiological processes of the human 
body. Many bioactive compounds of the M. charantia 
fruit, in addition to cations and vitamins, were studied 
and classified as carbohydrates, proteins, lipids and 
others [20]. It has triterpenoids [46], saponins [47], 
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polypeptides, flavonoids, alkaloids and sterols [46]. 
Several studies have reported the different bioactive 
components and their related functions [46]. Other 
studies have shown that M. charantia is a great source 
of antioxidant under experimental conditions. In fact, 
it was found to possess an activity against oxidant 
damage in vitro and in vivo [48-52]. Both the pulp and 
extracts of M. charantia followed by the seed powder 
and its ethanol/water extracts exhibited stronger anti-
oxygenic activity than other solvent extracts as 
determined via several in vitro models. In diabetic rats, 
administering supplementation of M. charantia (13.33 
g/kg) resulted in a significant rise of anti-oxidants 
(SOD, CAT and GST) activities [53, 54]. Flavonoids 
are known to be one of the most effective free radical 
scavengers and antioxidants from M. charantia. The 
antioxidant capacity enhanced gradually with the 
increase of flavonoid concentration [55]. Steroidal 
saponins, which are active ingredients of M. charantia, 
can decrease gluconeogenesis, increase glucose 
metabolism and tolerance by affecting the expression 
of the peroxisome proliferator-activated receptor alpha 
and gamma (PPARα and PPAR), which may mitigate 
insulin resistance, and a protein extract that exerted 
insulin-mimetic activities [56, 57]. 
 
 
Other Medical Properties of M. charantia 
 
M. charantia is a useful plant for human health and 
one of the most promising plants for cancer, obesity 
and diabetes treatment and prevention [46]. M. 
charantia helps in the entire digestion process by 
stimulating the secretion of gastric juices. It is very 
helpful in stimulating liver for secretion of bile juices 
that are very essential for metabolism of fats. It helps 
in improving the peristaltic movements and hence, it is 
very helpful in avoiding gastric disturbances [58]. It 
was reported that charantin, which is an active fraction 
of M. charantia, when it is administered to healthy 
rabbits, it produced a fall in blood sugar level. Another 
study found that pancreatectomy was reduced, but not 
abolished by the hypoglycemic effect of charantin, 
indicating a dual mechanism of action [58]. 
Furthermore, it is known to have anti-lipolytic 
properties. Recent research reports suggest that its 
extracts may ameliorate a high fat diet, which induced 
obesity and hyperlipidemia in animal models. Most 
findings related to obesity and hyperlipidemia also 
showed that plant extracts may modulate fat, 
metabolizing kinases such as AMPKs, genes, and 
affected adipocyte differentiation [56]. Moreover, it is 
a good source of all essential vitamins, such as vitamin 
A, thiamine, riboflavin, and vitamin C, and minerals 
like iron. Moreover, it is anti-inflammatory, anti-
cancer, anti-hypertensive and astringent. It has specific 
action on bowel movements [22]. As indicated earlier, 
M. charantia is also rich in the anti-oxidants caffeic 
and celuic acids and minerals, including potassium, 
calcium, zinc, magnesium, phosphorus and iron, and it 
is a good source of dietary fiber [22]. 
 
 
Clinical Studies of M. charantia 
 
An earlier study on the development of diabetic 
cataracts demonstrated that blood sugar level-
dependent cataract formation was slowed down by the 
consumption of bitter gourd fruit extract in association 
with better glucose homeostasis [59]. Today, processed 
bitter melon, in the form of capsules or tablets is 
commonly advertised and sold commercially. The 
products are marketed under the brand name 
Glucobetic in Canada, India, the United Kingdom, the 
United States, and in many Asian countries. Products 
can also be ordered online [59]. Compared with animal 
studies, clinical studies regarding the hypoglycemic 
effects of M. charantia have been sparse and sporadic. 
Lakholia, a physician, was probably the first person to 
document the therapeutic effect of bitter melon in 
1956, using himself as the subject. Table 1 shows other 
clinical studies which have been done on M charantia 
in diabetic patients [60]. 
 
 
 
 
Table 1. Some clinical studies, which employed M. charantia to treat diabetes 
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Study  
design 
Subjects Form(s) of M. charantia 
administered 
Treatment 
duration 
Outcome measured Statistical 
significance 
Reference 
Double-blind 
randomized 
controlled trial 
40 with T2D 
(twenty trial and 
twenty control 
subjects) 
Commercial herbal 
supplement capsules 
3 months HbA1c No [61] 
Controlled 
trial 
15 with T2D in 
3 groups 
Methanol extract of 
ground whole fruit 
1 week Fasting + postprandial 
blood glucose 
Yes [62] 
Randomized 
controlled trial 
50 with T2D 
(26 trial and  
24 control 
subjects) 
Tablets from dried 
whole fruit 
4 weeks (1) Fasting  
postprandial blood  
Glucose  
(2) Fructose amine 
No [63] 
Controlled 
trial 
Trial subjects:  
9 DM Control  
subjects:  
5 DM + 5 normal 
Aqueous extract refined 
to subcutaneous 
 injection (v- insulin) 
Single 
treatment 
Blood glucose Yes [64] 
 
 
LDL = low density lipoprotein; (-) reduced insulting effect by BM. 
Figure 2. A flow diagram illustrating the beneficial effects of bitter melon (BM) in preventing sudden cardiac death in obesity- 
induced diabetes mellitus. This study proposes that BM has a direct anti-oxidant effect on obesity, diabetes-induced 
hyperlipidemia and hyperglycemia and indirectly either delaying or preventing the development of hypertension, dyslipidemia, 
oxidative stress and fibrosis in the myocardium.  
 
 
Beneficial Effects of Bitter Melon on  
the Cardiovascular System 
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The flow chart in Figure 2 illustrates the beneficial 
effects of bitter melon in either preventing or delaying 
sudden cardiac death induced by diabetes. Obesity and 
other risk factors can induce diabetes, which in turn 
elicits a cascade of cellular and molecular events, 
including an elevation in blood glucose and lipids, 
which induces hypertension, dyslipidemia, oxidative 
stress, fibrosis, DCM, arrhythmia and SCD. Bitter 
melon, on the other hand, has a major therapeutic role 
in delaying and possibly preventing DCM. A number 
of studies, including unpublished recent data from our 
laboratory, showed that bitter melon juice or extract 
can reduce BMI, high blood pressure, elevated blood 
glucose, total lipids and triglycerides following 
treatment. Sustained hypertension is well known to be 
able to elicit heart failure and high levels of cholesterol, 
especially low-density lipoprotein (LDL) which can be 
deposited in coronary arteries in the heart to form 
plaques, thereby increasing the risk of heart diseases 
and even SCD [65-70]. 
 
 
Conclusion 
 
Both obesity and DM are major global metabolic 
health disorders, which can lead to damage and 
subsequent failure to a number of organs in the body, 
including the heart. M. charantia is a useful plant for 
human health and one of the most promising plants for 
obesity and diabetes treatment and prevention. Also, it 
is composed of chemicals, which have anti-oxidant 
properties and hypoglycemic activity similar to insulin. 
The cellular and molecular mechanisms underlying the 
mechanisms related to its anti-diabetic and anti-oxidant 
properties is not fully clear and further research should 
be done. However, it is a rich source of potential 
chemically novel medicinal compounds, vitamins, 
cations and fibers, which need more attention for 
screening against new targets in the future. The present 
review supports the need for better-designed clinical 
trials with sufficient sample size and statistical power 
to further indicate the acclaimed efficacy of M. 
charantia as a natural nutritional treatment for DM and 
related diseases. In particular, M. charantia may be a 
feasible cost–effective option for people who have a 
high prevalence of obesity, diabetes and CVDs but 
prefer treatment based on natural products according to 
their economic status and cultural beliefs. 
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